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Introduction
The vitamin D system includes a group of fat-soluble pro-
hormones and their respective metabolites. Reduced levels
of vitamin D3 are linked with decrease of calcium and
bone homeostasis, the onset and progression of various
diseases such as autoimmune diseases, respiratory infec-
tions, diabetes mellitus type 1 and type 2, hypertension
and cardiovascular disorders, and cancers (breast, colon,
liver, stomach and prostate).
This study aimed to investigate vitamin D metabolism
by measuring 25(OH)D3, 1,25 (OH)2D3, PTH and calcium
concentrations in the peripheral blood of patients with
different forms of thyroid tumours.
Patients and methods
Vitamin D [25(OH)D3 and 1,25(OH)2D3], PTH and
calcium serum levels of 50 consecutive patients with
epithelial thyroid cancer: 27 cases of papillary cancers
(PTC), 16 follicular cancers (FTC), seven cases of anaplas-
tic cancers (ATC), and 34 multinodular nontoxic goiter
(MNG) were measured by specific immunoassay. The con-
trol group consisted of 26 healthy volunteers.
Results
The results revealed significantly lower 1,25 (OH)2D3 con-
centration in the PTC group (22.67 pg/ml ± 8.12; p <0.05),
FTC group (16.09 pg/ml ± 6.15; p <0.02) and ATC group
(9.48 pg/ml ± 5.18; p <0.02) versus controls. Levels of 1,25
(OH)2D3 varied by cancer stage and were also significantly
different. A significant decrease in circulating 1,25 (OH)
2D3 concentration was found in patients with stage I
(24.12 pg/ml ± 6.77; p <0.05), stage II (16.93 pg/ml ± 4.55;
p <0.05), stage III (12.44 ± 8.98; p <0.02) and in stage IVa
(6.18 ± 2.22; p <0.01) of cancer. There were no differences
when comparing serum levels of 25(OH)D3, PTH or cal-
cium concentrations among individuals with multinodular
goiter, thyroid cancer and age- and sex-matched control
volunteers.
Conclusions
Our study revealed that impaired vitamin D3 metabo-
lism may play an important role in thyroid follicular cell
oncogenesis.
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